These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29454983)

  • 1. Old and new glycopeptide antibiotics: From product to gene and back in the post-genomic era.
    Marcone GL; Binda E; Berini F; Marinelli F
    Biotechnol Adv; 2018; 36(2):534-554. PubMed ID: 29454983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and manipulating glycopeptide pathways: the example of the dalbavancin precursor A40926.
    Sosio M; Donadio S
    J Ind Microbiol Biotechnol; 2006 Jul; 33(7):569-76. PubMed ID: 16761167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopeptide antibiotics: back to the future.
    Butler MS; Hansford KA; Blaskovich MA; Halai R; Cooper MA
    J Antibiot (Tokyo); 2014 Sep; 67(9):631-44. PubMed ID: 25118105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old and New Glycopeptide Antibiotics: Action and Resistance.
    Binda E; Marinelli F; Marcone GL
    Antibiotics (Basel); 2014 Nov; 3(4):572-94. PubMed ID: 27025757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformations of lipoglycopeptides to obtain novel antibiotics.
    Gandolfi R; Jovetic S; Marinelli F; Molinari F
    J Antibiot (Tokyo); 2007 Apr; 60(4):265-71. PubMed ID: 17456978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopeptide antibiotic discovery in the genomic era.
    Xu M; Wang W; Wright GD
    Methods Enzymol; 2022; 665():325-346. PubMed ID: 35379441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by
    Yushchuk O; Vior NM; Andreo-Vidal A; Berini F; Rückert C; Busche T; Binda E; Kalinowski J; Truman AW; Marinelli F
    ACS Chem Biol; 2021 May; 16(5):915-928. PubMed ID: 33913701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex Regulatory Networks Governing Production of the Glycopeptide A40926.
    Alduina R; Sosio M; Donadio S
    Antibiotics (Basel); 2018 Apr; 7(2):. PubMed ID: 29621136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, Properties, and Mechanism of Action of New Generation of Polycyclic Glycopeptide Antibiotics.
    Olsufyeva EN; Tevyashova AN
    Curr Top Med Chem; 2017; 17(19):2166-2198. PubMed ID: 28137232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of Induction of Glycopeptide Antibiotic Resistance in the Producing Actinomycetes.
    Binda E; Cappelletti P; Marinelli F; Marcone GL
    Antibiotics (Basel); 2018 Apr; 7(2):. PubMed ID: 29693566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL; Yang G
    Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward Single-Peak Dalbavancin Analogs through Biology and Chemistry.
    Alt S; Bernasconi A; Sosio M; Brunati C; Donadio S; Maffioli SI
    ACS Chem Biol; 2019 Mar; 14(3):356-360. PubMed ID: 30830742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.